Daclatasvir combined with asunaprevir is a cost-effective and cost-saving treatment for hepatitis C infection in China. [electronic resource]
Producer: 20191101Description: 785-795 p. digitalISSN:- 2042-6313
- Antiviral Agents -- administration & dosage
- Carbamates
- China
- Cost-Benefit Analysis
- Drug Therapy, Combination
- Genotype
- Health Expenditures
- Health Resources -- economics
- Hepatitis C, Chronic -- drug therapy
- Humans
- Imidazoles -- administration & dosage
- Isoquinolines -- administration & dosage
- Life Expectancy
- Male
- Markov Chains
- Models, Econometric
- Pyrrolidines
- Quality-Adjusted Life Years
- Sulfonamides -- administration & dosage
- Valine -- analogs & derivatives
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.